LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Portola Pharmaceuticals, Inc. (“Portola” or the “Company”) (NASDAQ: PTLA) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Portola investigation page on our website at https://www.glancylaw.com/case/portola-pharmaceuticals-inc
On September 5, 2017, Portola disclosed that the approval and launch date of its oral anticoagulant Bevyxxa (betrixaban) would be delayed. The Company further stated that its “best estimate” for the timing of the product release is now the first quarter of 2018, but the Company also stated that there is a possibility of an even longer delay.
On this news, Portola's share price dropped as much as $3.83, or 6.44% on September 6, 2017.
If you purchased Portola securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley F. Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.